Unilateral dopamine depletion paradoxically enhances amphetamine-induced Fos expression in basal ganglia output structures.
The ability of amphetamine to induce expression of the immediate early gene protein, Fos, was examined by immunocytochemistry in animals with unilateral 6-hydroxydopamine lesions of the nigrostriatal bundle. Amphetamine induced Fos expression in the globus pallidus (GP) on the intact side of the brain, but this response was greatly attenuated on the dopamine-depleted side. In contrast, amphetamine induced little Fos expression in the entopeduncular nucleus (EPN) and the substantia nigra pars reticulata (SNpr) on the intact side of the brain, but resulted in pronounced expression in these structures on the lesioned side. These findings demonstrate that unilateral dopamine depletion results in a pathophysiological state in which some responses to amphetamine are attenuated while others are paradoxically potentiated. One explanation of these effects is that amphetamine may indirectly activate excitatory inputs to the SNpr and the EPN on both sides of the brain. On the intact side, these effects would be opposed by the simultaneous activation of inhibitory pathways arising in the striatum and the GP, with the result that little Fos expression would be seen. On the dopamine-depleted side, however, engagement of these inhibitory pathways would be attenuated and the unopposed effects of the excitatory inputs mobilized by amphetamine would result in exaggerated Fos synthesis.
Wirtshafter
D
D
Department of Psychology, M/C 285, The University of Illinois at Chicago, 1007 West Harrison St., Chicago, IL 60607-7137, USA. davew@uic.edu
Asin
K E
KE
D000344:Afferent Pathways / Q000378:metabolism; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004298:Dopamine / Q000172:deficiency*; D015259:Dopamine Agents / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D016627:Oxidopamine / Q000494:pharmacology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
D015259:Dopamine Agents; D016760:Proto-Oncogene Proteins c-fos; D016627:Oxidopamine; D000661:Amphetamine; D004298:Dopamine